Perindopril isa long-acting, once-daily lipophilic anglotensln-converting enzyme Inhlbltor with high tissue angiotensln-converting enzyme afflnity, lowering angiotensin Il and potentiating bradyklnln. Its efflcacy, safety and tolerabillty are well established In the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropeantrial on Reduction Of cardiac events wlth Perindopril in stable coronary Artery disease (EUROPA)and Perindopril pROtectlon aGainst REcurrentStroke Study (PROGRESSh),ave shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether hypertensive or notoThus,the outcome of these and other trials support the concept of cardiovascular protective properties of anglotensln-converting enzyme inhibition with perindoprllin addltlon to the obvious blood-pressure-Iowering effect. Considering its properties and the gathered clinical evldence on efflcacy and tolerability, perlndopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular dlsease management (1) and should therefore be consldered as a first-line antihypertensive agent, formlng a consistent part of the comprehensive strategy agalnst hypertension and related cardiovascular complications.
Angiotensin-converting enzyme inhibition in cardiovascular disease evidence with perindopril
FERRARI, Roberto
2005
Abstract
Perindopril isa long-acting, once-daily lipophilic anglotensln-converting enzyme Inhlbltor with high tissue angiotensln-converting enzyme afflnity, lowering angiotensin Il and potentiating bradyklnln. Its efflcacy, safety and tolerabillty are well established In the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropeantrial on Reduction Of cardiac events wlth Perindopril in stable coronary Artery disease (EUROPA)and Perindopril pROtectlon aGainst REcurrentStroke Study (PROGRESSh),ave shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether hypertensive or notoThus,the outcome of these and other trials support the concept of cardiovascular protective properties of anglotensln-converting enzyme inhibition with perindoprllin addltlon to the obvious blood-pressure-Iowering effect. Considering its properties and the gathered clinical evldence on efflcacy and tolerability, perlndopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular dlsease management (1) and should therefore be consldered as a first-line antihypertensive agent, formlng a consistent part of the comprehensive strategy agalnst hypertension and related cardiovascular complications.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
